Potentially high number of ineffective drugs with the standard shorter course regimen for multidrug-resistant tuberculosis treatment in Haiti

Kathleen F. Walsh, Ariadne Souroutzidis, Stalz Charles Vilbrun, Miranda Peeples, Guy Joissaint, Sobieskye Delva, Pamphile Widmann, Gertrude Royal, Jake Pry, Heejung Bang, Jean W. Pape, Serena P. Koenig

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Multidrug-resistant tuberculosis (MDR-TB) outcomes are poor partly because of the long treatment duration; the World Health Organization conditionally recommends a shorter course regimen to potentially improve treatment outcomes. Here,we describe the drug susceptibility patterns of a cohort ofMDR-TBpatients inHaiti and determine the number of likely effective drugs if they were treated with the recommended shorter course regimen. We retrospectively examined drug susceptibility patterns of adults initiatingMDR-TBtreatment between 2008 and 2015 at the HaitianGroup for the Study of Kaposi's Sarcoma andOpportunistic Infections in Port-au-Prince, Haiti. First- and second-line drug susceptibility testing (DST) was analyzed and used to determine the number of presumed effective drugs. Of the 239 patients analyzed, 226 (95%), 183 (77%), 135 (57%), and 38 (16%) isolates were resistant to high-dose isoniazid, ethambutol, pyrazinamide, and ethionamide, respectively. Eight patients (3%) had resistance to either a fluoroquinolone or a second-line injectable and none had extensively resistant TB. Of the 239 patients, 132 (55%) would have fewer than five likely effective drugs in the intensive phase of the recommended shorter course regimen and121 (51%)would have two or fewer likely effective drugs in the continuation phase.Because of the high rates of resistance to first-line TBmedications, about 50%ofMDR-TB patients would be left with only two effective drugs in the continuation phase of the recommended shorter course regimen, raising concerns about the effectiveness of this regimen in Haiti and the importance of using DST to guide treatment.

Original languageEnglish (US)
Pages (from-to)392-398
Number of pages7
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume100
Issue number2
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Haiti
Multidrug-Resistant Tuberculosis
Pharmaceutical Preparations
Therapeutics
Ethionamide
Pyrazinamide
Ethambutol
Kaposi's Sarcoma
Fluoroquinolones
Isoniazid

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Virology

Cite this

Potentially high number of ineffective drugs with the standard shorter course regimen for multidrug-resistant tuberculosis treatment in Haiti. / Walsh, Kathleen F.; Souroutzidis, Ariadne; Vilbrun, Stalz Charles; Peeples, Miranda; Joissaint, Guy; Delva, Sobieskye; Widmann, Pamphile; Royal, Gertrude; Pry, Jake; Bang, Heejung; Pape, Jean W.; Koenig, Serena P.

In: American Journal of Tropical Medicine and Hygiene, Vol. 100, No. 2, 01.01.2019, p. 392-398.

Research output: Contribution to journalArticle

Walsh, KF, Souroutzidis, A, Vilbrun, SC, Peeples, M, Joissaint, G, Delva, S, Widmann, P, Royal, G, Pry, J, Bang, H, Pape, JW & Koenig, SP 2019, 'Potentially high number of ineffective drugs with the standard shorter course regimen for multidrug-resistant tuberculosis treatment in Haiti', American Journal of Tropical Medicine and Hygiene, vol. 100, no. 2, pp. 392-398. https://doi.org/10.4269/ajtmh.18-0493
Walsh, Kathleen F. ; Souroutzidis, Ariadne ; Vilbrun, Stalz Charles ; Peeples, Miranda ; Joissaint, Guy ; Delva, Sobieskye ; Widmann, Pamphile ; Royal, Gertrude ; Pry, Jake ; Bang, Heejung ; Pape, Jean W. ; Koenig, Serena P. / Potentially high number of ineffective drugs with the standard shorter course regimen for multidrug-resistant tuberculosis treatment in Haiti. In: American Journal of Tropical Medicine and Hygiene. 2019 ; Vol. 100, No. 2. pp. 392-398.
@article{0924b85f1eae4e6e878d5c0982d5ec20,
title = "Potentially high number of ineffective drugs with the standard shorter course regimen for multidrug-resistant tuberculosis treatment in Haiti",
abstract = "Multidrug-resistant tuberculosis (MDR-TB) outcomes are poor partly because of the long treatment duration; the World Health Organization conditionally recommends a shorter course regimen to potentially improve treatment outcomes. Here,we describe the drug susceptibility patterns of a cohort ofMDR-TBpatients inHaiti and determine the number of likely effective drugs if they were treated with the recommended shorter course regimen. We retrospectively examined drug susceptibility patterns of adults initiatingMDR-TBtreatment between 2008 and 2015 at the HaitianGroup for the Study of Kaposi's Sarcoma andOpportunistic Infections in Port-au-Prince, Haiti. First- and second-line drug susceptibility testing (DST) was analyzed and used to determine the number of presumed effective drugs. Of the 239 patients analyzed, 226 (95{\%}), 183 (77{\%}), 135 (57{\%}), and 38 (16{\%}) isolates were resistant to high-dose isoniazid, ethambutol, pyrazinamide, and ethionamide, respectively. Eight patients (3{\%}) had resistance to either a fluoroquinolone or a second-line injectable and none had extensively resistant TB. Of the 239 patients, 132 (55{\%}) would have fewer than five likely effective drugs in the intensive phase of the recommended shorter course regimen and121 (51{\%})would have two or fewer likely effective drugs in the continuation phase.Because of the high rates of resistance to first-line TBmedications, about 50{\%}ofMDR-TB patients would be left with only two effective drugs in the continuation phase of the recommended shorter course regimen, raising concerns about the effectiveness of this regimen in Haiti and the importance of using DST to guide treatment.",
author = "Walsh, {Kathleen F.} and Ariadne Souroutzidis and Vilbrun, {Stalz Charles} and Miranda Peeples and Guy Joissaint and Sobieskye Delva and Pamphile Widmann and Gertrude Royal and Jake Pry and Heejung Bang and Pape, {Jean W.} and Koenig, {Serena P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.4269/ajtmh.18-0493",
language = "English (US)",
volume = "100",
pages = "392--398",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "2",

}

TY - JOUR

T1 - Potentially high number of ineffective drugs with the standard shorter course regimen for multidrug-resistant tuberculosis treatment in Haiti

AU - Walsh, Kathleen F.

AU - Souroutzidis, Ariadne

AU - Vilbrun, Stalz Charles

AU - Peeples, Miranda

AU - Joissaint, Guy

AU - Delva, Sobieskye

AU - Widmann, Pamphile

AU - Royal, Gertrude

AU - Pry, Jake

AU - Bang, Heejung

AU - Pape, Jean W.

AU - Koenig, Serena P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Multidrug-resistant tuberculosis (MDR-TB) outcomes are poor partly because of the long treatment duration; the World Health Organization conditionally recommends a shorter course regimen to potentially improve treatment outcomes. Here,we describe the drug susceptibility patterns of a cohort ofMDR-TBpatients inHaiti and determine the number of likely effective drugs if they were treated with the recommended shorter course regimen. We retrospectively examined drug susceptibility patterns of adults initiatingMDR-TBtreatment between 2008 and 2015 at the HaitianGroup for the Study of Kaposi's Sarcoma andOpportunistic Infections in Port-au-Prince, Haiti. First- and second-line drug susceptibility testing (DST) was analyzed and used to determine the number of presumed effective drugs. Of the 239 patients analyzed, 226 (95%), 183 (77%), 135 (57%), and 38 (16%) isolates were resistant to high-dose isoniazid, ethambutol, pyrazinamide, and ethionamide, respectively. Eight patients (3%) had resistance to either a fluoroquinolone or a second-line injectable and none had extensively resistant TB. Of the 239 patients, 132 (55%) would have fewer than five likely effective drugs in the intensive phase of the recommended shorter course regimen and121 (51%)would have two or fewer likely effective drugs in the continuation phase.Because of the high rates of resistance to first-line TBmedications, about 50%ofMDR-TB patients would be left with only two effective drugs in the continuation phase of the recommended shorter course regimen, raising concerns about the effectiveness of this regimen in Haiti and the importance of using DST to guide treatment.

AB - Multidrug-resistant tuberculosis (MDR-TB) outcomes are poor partly because of the long treatment duration; the World Health Organization conditionally recommends a shorter course regimen to potentially improve treatment outcomes. Here,we describe the drug susceptibility patterns of a cohort ofMDR-TBpatients inHaiti and determine the number of likely effective drugs if they were treated with the recommended shorter course regimen. We retrospectively examined drug susceptibility patterns of adults initiatingMDR-TBtreatment between 2008 and 2015 at the HaitianGroup for the Study of Kaposi's Sarcoma andOpportunistic Infections in Port-au-Prince, Haiti. First- and second-line drug susceptibility testing (DST) was analyzed and used to determine the number of presumed effective drugs. Of the 239 patients analyzed, 226 (95%), 183 (77%), 135 (57%), and 38 (16%) isolates were resistant to high-dose isoniazid, ethambutol, pyrazinamide, and ethionamide, respectively. Eight patients (3%) had resistance to either a fluoroquinolone or a second-line injectable and none had extensively resistant TB. Of the 239 patients, 132 (55%) would have fewer than five likely effective drugs in the intensive phase of the recommended shorter course regimen and121 (51%)would have two or fewer likely effective drugs in the continuation phase.Because of the high rates of resistance to first-line TBmedications, about 50%ofMDR-TB patients would be left with only two effective drugs in the continuation phase of the recommended shorter course regimen, raising concerns about the effectiveness of this regimen in Haiti and the importance of using DST to guide treatment.

UR - http://www.scopus.com/inward/record.url?scp=85061234941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061234941&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.18-0493

DO - 10.4269/ajtmh.18-0493

M3 - Article

C2 - 30594266

AN - SCOPUS:85061234941

VL - 100

SP - 392

EP - 398

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 2

ER -